Are there any restrictions for vascepa coverage?

Vascepa, a medication containing icosapent ethyl, is a prescription drug that has been shown to reduce cardiovascular risk in certain patients.

According to the Vascepa label [1], coverage for this medication is restricted in some cases. For example, Vascepa must be prescribed by a healthcare provider, and the patient must meet specific clinical criteria, such as having a history of cardiovascular disease or having a high risk of cardiovascular events [1].

Additionally, insurance coverage for Vascepa may be limited due to its high cost. In 2022, a ruling by the US International Trade Commission allowed Vascepa manufacturer Amarin to exclude the patent for the medication, which allowed generic versions of Vascepa to be developed, reducing the cost, but this change didn't happen in 2022, and we can expect generic versions of Vascepa available in early 2024 [2]. Generic versions of Vascepa are expected to lower the cost of the medication, making more patients eligible for coverage [3].

Drug manufacturers and pharmaceutical organizations, such as Amarin, offer copay cards and patient assistance programs to help eligible patients with Vascepa costs. However, these programs may have their own eligibility requirements and do not necessarily guarantee full coverage or a lower copayment.

Patients who are prescribed Vascepa should contact their insurance provider and manufacturer's customer service department to inquire about specific coverage and cost information, or to use a resource like DrugPatentWatch.com for more information on available options [4].

Sources:
1. [http://vascepa label.com](http://vascepa label.com)
2. https://www.pharmaciststechnician.com/news/article/2023/04/amarin-vascaepa-generic-versions-likely-in-2024
3. https://www.medpagetoday.com/cardiology/clinical-trials/100144
4. https://www.drugpatentwatch.com/